Oncólogo molecularmente incorrecto. Círculos, cuadrados, linfocitos cabreados. Escribo una #novela. #melanoma #immunotherapy #genetics. Opinions are my own!😇
Joined November 2012
- Tweets9.1K
- Following1.4K
- Followers2.2K
- Likes5K
Pinned Tweet
Happy to share the final results of the 🇪🇸 & 🇫🇷 ph2 trial of intratumoral BO-112 + pembro for patients with anti PD-1 resistant #melanoma. 25% ORR and 54% patients alive at 2 years. 16 years of basic and clinical research behind. Some context here 👇🧵
ascopubs.org/doi/10.1200/JCO…
Iván Márquez Rodas 🇪🇦 retweeted
🔬 #ESMO26 | El Dr. @ivanpantic1980, portavoz de SEOM y presidente del @GrupoMelanoma, analiza INTerpath-001 (LBA1), presentado en la Sesión Presidencial de @myESMO 2026.
🧬 Primera fase III positiva de una terapia individualizada de neoantígenos basada en ARNm en melanoma #ESMO26
Iván Márquez Rodas 🇪🇦 retweeted
Thank you @ivanpantic1980
I am very happy you enjoyed it. It was indeed a out of the box idea - showing how we can learn, and moreover do cross-fertilization from other tumor areas, and an academic trial! Congratulations for the great effort.
Iván Márquez Rodas 🇪🇦 retweeted
Novedades en melanoma del #ESMO26. Empezamos con STARBOARD (fase 3): encorafenib + binimetinib + pembrolizumab vs pembrolizumab en 1L BRAF V600. SLP 33,0 vs 3,4 m (HR 0,33), ORR 70% vs 32,7%. Pero: 70% TRAE G≥3, 42,7% suspende BRAF/MEKi y brazo control discutible.
My personal take on the (again) NADINA up date: we cannot omit adjuvant therapy in near pCR; only in pCR #melanoma #ESMO2026 @GrupoMelanoma . Before making decisions from asumptions from small trials, we should think about how we translate them into confirmatory trials.
This is a great achievement for our @GrupoMelanoma In around 6m, the group managed to include all the patients, with an out of the box idea in one single country. Brilliant presentation by @g_develasco Thanks to @myESMO for selecting it & @TeresaSAmaral for her great discussion
🚨 #ESMO26 | PLUG-IN GEM 2301
Enfortumab vedotin + pembro in anti–PD-1–refractory advanced melanoma (N=60):
▪️ Confirmed ORR 25% | DCR 55%
• BRAF WT: ORR 21.4%
• BRAF-mut: ORR 33.3%
• Acral 33.3% | Mucosal 20.0% confirmed ORR
Safety with no new signals!
Interestingly, Nectin-4 expression did not identify responders….exploratory, but worth watching 🤔
A new ADC signal in refractory melanoma…this PLUG-IN deserves to stay connected 🔌
Congrats to @g_develasco and all the @GrupoMelanoma team! 👏🏼
@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma
RT @MarioBalsaMD: 🚨 #ESMO26 | PLUG-IN GEM 2301
Enfortumab vedotin + pembro in anti–PD-1–refractory advanced melanoma (N=60):
▪️ Confirmed…
Iván Márquez Rodas 🇪🇦 retweeted
🚨 One of the big melanoma moments of #ESMO26!
INTerpath-001 is positive, but the most interesting part may be the questions it opens:
1. Who benefits most?
2. Will the RFS benefit translate into OS?
3. And where does a personalized mRNA vaccine fit in the neoadjuvant era?
My #OAOnTheGo take 👇
@OncoAlert @myESMO @_SEOM @GrupoMelanoma
@hospitalclinic
#ClínicBarcelonaComprehensiveCancerCenter
🎥 #OAOnTheGO | OncoAlert at #ESMO26 Madrid
INTerpath-001 is positive! 🔬
@ProfGLongMIA @jasonlukemd
Dr. Mario Balsa (@HospitalClínic Barcelona) discusses pembrolizumab + personalized mRNA vaccine V940 in resected melanoma.
📊 2-year RFS: 82% vs 60% (HR 0.58)
📊 DMFS: 88.5% vs 80.2% (HR 0.62)
Will this translate into longer survival? Who benefits most? And how does it fit with neoadjuvant immunotherapy?
🎬 Watch now!
#Melanoma #OncoAlert
@DrBetofMDPhD, @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
Iván Márquez Rodas 🇪🇦 retweeted
👑 Presidential #ESMO26! INTerpath-001: personalized mRNA vaccination reaches phase III in melanoma.
Resected stage IIB–IV melanoma, N=1,137: intismeran + pembrolizumab vs pembrolizumab.
💥 At 24 months:
• RFS: 82.2% vs 70.0% → HR 0.58
• DMFS: 88.5% vs 80.2% → HR 0.62
• Absolute gains: +12.2% RFS / +8.3% DMFS
• Benefit emerges mainly after 6 months
• Grade ≥3 AEs: 23.6% vs 20.3%
• OS still immature
A clinically meaningful new mechanism, but the real question now is positioning 🤔
For macroscopic stage III: adjuvant personalized vaccine after surgery, or neoadjuvant ipi/nivo before it? Biomarkers may ultimately decide.
Congrats to @ProfGLongMIA and all the team! 👏🏼
@OncoAlert
@OncoReporte @myESMO @_SEOM @GrupoMelanoma
These are the kind of reflections that appears after seing the data, and not based on speculations driven by casino-markets. Thank you for your sensible comment! @YannickBuccella
So the “not-so-official-anymore“ presentation is in: The melanoma vaccine works. We knew that, 82% recurrence-free at two years vs 70% with immunotherapy alone.
It's built individually for each patient, the logistics are enormous: Sequence their tumor, design the vaccine, manufacture it for one person. Weeks of work that will cost a fortune.
A treatment like that doesn't scale to most of the world. It scales to countries that can afford a factory run per patient. I live in a country which happens to be able to afford that, most countries can’t. Melanoma kills people everywhere. This will reach a fraction of them.
Solving cancer and solving access are two different problems. We just got better at the first one.
Iván Márquez Rodas 🇪🇦 retweeted
So the “not-so-official-anymore“ presentation is in: The melanoma vaccine works. We knew that, 82% recurrence-free at two years vs 70% with immunotherapy alone.
It's built individually for each patient, the logistics are enormous: Sequence their tumor, design the vaccine, manufacture it for one person. Weeks of work that will cost a fortune.
A treatment like that doesn't scale to most of the world. It scales to countries that can afford a factory run per patient. I live in a country which happens to be able to afford that, most countries can’t. Melanoma kills people everywhere. This will reach a fraction of them.
Solving cancer and solving access are two different problems. We just got better at the first one.
Iván Márquez Rodas 🇪🇦 retweeted
e-highlights ESMO 2026 - Día 1: Informe 1
groupgem.es/informes-esmo-2/
Aquí, de tranquis; a escuchar la plenaria, que me han dicho que no hay nada de polémica ni expectacióm alguna @GrupoMelanoma #melanoma @myESMO
No plenary can start until @GrupoMelanoma has its GEMinolas to feed the discussion! Lets go!!!
Iván Márquez Rodas 🇪🇦 retweeted
📍 Madrid #ESMO2026
Del 23-27/OCT la comunidad oncológica internacional comparte últimos avances en melanoma, inmunoterapia, medicina de precisión e investigación traslacional Desde GEMM comunicaremos las novedades con potencial impacto en práctica clínica y en nuestros pacientes
Iván Márquez Rodas 🇪🇦 retweeted
No te pierdas lo importante: Los estudios derivados del registro GEM y los ensayos del grupo. España se mueve en melanoma @ivanpantic1980 @boutrosand
En este #esmo2026 habrá largas colas de la curva y larguísimas colas de comida 😅
Iván Márquez Rodas 🇪🇦 retweeted
Some thoughts on the INTerpath-001 backlash, and the simplistic "neoadjuvant already does better, so why bother" take. I think it misses a few important things.
➡️ First, the neoadjuvant data (S1801, NADINA) come from patients with macroscopic, clinically detectable nodal disease. INTerpath-001 also includes node-negative IIB/IIC and patients whose nodal disease only showed up on sentinel node biopsy. In the big SLN trials, about two thirds of SLN+ patients had deposits ≤1 mm. None of these patients are neoadjuvant candidates. We see the same confusion in #NSCLC all the time, when people compare stage IIIA from adjuvant trials (pathological staging) with stage IIIA from neoadjuvant trials (clinical staging). Same stage on paper, not the same patients.
➡️ Second, INTerpath-001 was designed before NADINA read out, when adjuvant anti-PD-1 was still the default for resected stage III. Judging it against today's practice is a bit of hindsight.
➡️ Third, I suspect the most logical place for a neoantigen vaccine is after neoadjuvant ICI in patients who don't reach pCR. INTerpath-009 is already testing exactly this in NSCLC, so we'll get some hints there.
➡️ And all of this comes with only an absolute ~3% increase in grade ≥3 toxicity, which also belongs in the balance.
For macroscopic stage III, the critique lands. I want to see the full data and the stage breakdown at LBA1. But I'd be careful firing at this result before we've even seen it properly.
@OncoAlert @Larvol @KolPulseAI @_SEOM @myESMO
#Melanoma #ESMO26
Lo que está pasando con la vacuna mRNA en #melanoma es un friendly reminder de que el mercado no entiende las cosas como creemos que las entendemos nosotros.